FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1343-1349 May 8, 1997 Number 19 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants.

Methods Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells.

Results The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants.

Conclusions Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1.

Source Information

From the Department of Pediatrics, University of Massachusetts Medical School, Worcester (K.L., J.L.S.); the Department of Pediatrics, University of California at Los Angeles, Los Angeles (Y.B., P.K.); the Department of Pediatrics, University of Connecticut Medical School, Farmington (J.R.); the Department of Pediatrics, Baystate Medical Center, Springfield, Mass. (B.S.); and Boehringer–Ingelheim Pharmaceuticals, Ridgefield, Conn. (M.L., S.C.).

Address reprint requests to Dr. Luzuriaga at Pediatrics and Molecular Medicine, University of Massachusetts Medical School, Rm. 318, Biotech 2, 373 Plantation St., Worcester, MA 01605.

Full Text of this Article

This article has been cited by other articles:

• Brogly, S., Williams, P., Seage, G. R. III, Oleske, J. M., Van Dyke, R., McIntosh, K., for the PACTG 219C Team, (2005). Antiretroviral Treatment in Pediatric HIV Infection in the United States: From Clinical Trials to Clinical Practice. JAMA 293: 2213-2220 [Abstract] [Full Text]  
• Berk, D. R., Falkovitz-Halpern, M. S., Hill, D. W., Albin, C., Arrieta, A., Bork, J. M., Cohan, D., Nilson, B., Petru, A., Ruiz, J., Weintrub, P. S., Wenman, W., Maldonado, Y. A., for the California Pediatric HIV Study Group, (2005). Temporal Trends in Early Clinical Manifestations of Perinatal HIV Infection in a Population-Based Cohort. JAMA 293: 2221-2231 [Abstract] [Full Text]  
• Van Herrewege, Y., Vanham, G., Michiels, J., Fransen, K., Kestens, L., Andries, K., Janssen, P., Lewi, P. (2004). A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides. Antimicrob. Agents Chemother. 48: 3684-3689 [Abstract] [Full Text]  
• Feeney, M. E., Roosevelt, K. A., Tang, Y., Pfafferott, K. J., McIntosh, K., Burchett, S. K., Mao, C., Walker, B. D., Goulder, P. J. R. (2003). Comprehensive Screening Reveals Strong and Broadly Directed Human Immunodeficiency Virus Type 1-Specific CD8 Responses in Perinatally Infected Children. J. Virol. 77: 7492-7501 [Abstract] [Full Text]  
• Buseyne, F., Scott-Algara, D., Porrot, F., Corre, B., Bellal, N., Burgard, M., Rouzioux, C., Blanche, S., Riviere, Y. (2002). Frequencies of Ex Vivo-Activated Human Immunodeficiency Virus Type 1-Specific Gamma-Interferon-Producing CD8+ T Cells in Infected Children Correlate Positively with Plasma Viral Load. J. Virol. 76: 12414-12422 [Abstract] [Full Text]  
• Ruff, C. T., Ray, S. C., Kwon, P., Zinn, R., Pendleton, A., Hutton, N., Ashworth, R., Gange, S., Quinn, T. C., Siliciano, R. F., Persaud, D. (2002). Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure. J. Virol. 76: 9481-9492 [Abstract] [Full Text]  
• Resino, S, Bellon, J M, Sanchez-Ramon, S, Gurbindo, D, Ruiz-Contreras, J, Leon, J A, Ramos, J T, Munoz-Fernandez, M A (2002). Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch. Dis. Child. 86: 119-124 [Abstract] [Full Text]  
• Cooper, D. A. (2002). Update on Didanosine. J Int Assoc Physicians AIDS Care (Chic Ill) 1: 15-25 [Abstract]  
• Scott, Z. A., Chadwick, E. G., Gibson, L. L., Catalina, M. D., McManus, M. M., Yogev, R., Palumbo, P., Sullivan, J. L., Britto, P., Gay, H., Luzuriaga, K. (2001). Infrequent Detection of HIV-1-Specific, But Not Cytomegalovirus-Specific, CD8+ T Cell Responses in Young HIV-1-Infected Infants. J. Immunol. 167: 7134-7140 [Abstract] [Full Text]  
• Sullivan, J. L., Luzuriaga, K. (2001). The Changing Face of Pediatric HIV-1 Infection. NEJM 345: 1568-1569 [Full Text]  
• Hermankova, M., Ray, S. C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquila, R. T., Quinn, T. C., Siliciano, J. D., Siliciano, R. F., Persaud, D. (2001). HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy. JAMA 286: 196-207 [Abstract] [Full Text]  
• Lee, K., Chu, C. K. (2001). Molecular Modeling Approach to Understanding the Mode of Action of L-Nucleosides as Antiviral Agents. Antimicrob. Agents Chemother. 45: 138-144 [Abstract] [Full Text]  
• Sáez-Llorens, X., Nelson Jr, R. P., Emmanuel, P., Wiznia, A., Mitchell, C., Church, J. A., Sleasman, J., Van Dyke, R., Richardson, C. G., Cutrell, A., Spreen, W., Hetherington, S., the CNAA3006 Study Team, (2001). A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children. Pediatrics 107: 4e-4 [Abstract] [Full Text]  
• HART, C.A., BEECHING, N.J., DUERDEN, B.I. (2000). Infections in AIDS: Proceedings of the Sixth Liverpool Tropical School Bayer Symposium on Microbial Diseases held on 6 February 1999. J Med Microbiol 49: 947-967 [Full Text]  
• Luzuriaga, K., McManus, M., Catalina, M., Mayack, S., Sharkey, M., Stevenson, M. (2000). Early Therapy of Vertical Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Control of Viral Replication and Absence of Persistent HIV-1-Specific Immune Responses. J. Virol. 74: 6984-6991 [Abstract] [Full Text]  
• Starr, S. E., Fletcher, C. V., Spector, S. A., Yong, F. H., Fenton, T., Brundage, R. C., Manion, D., Ruiz, N. M., Gersten, M., Becker, M., McNamara, J., Mofenson, L. M., The Pediatric AIDS Clinical Trials Group 382 Team, (1999). Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. NEJM 341: 1874-1881 [Abstract] [Full Text]  
• Lindegren, M. L., Byers, R. H. Jr, Thomas, P., Davis, S. F., Caldwell, B., Rogers, M., Gwinn, M., Ward, J. W., Fleming, P. L. (1999). Trends in Perinatal Transmission of HIV/AIDS in the United States. JAMA 282: 531-538 [Abstract] [Full Text]  
• van Rompay, K. K. A., Dailey, P. J., Tarara, R. P., Canfield, D. R., Aguirre, N. L., Cherrington, J. M., Lamy, P. D., Bischofberger, N., Pedersen, N. C., Marthas, M. L. (1999). Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques. J. Virol. 73: 2947-2955 [Abstract] [Full Text]  
• Luzuriaga, K., Wu, H., McManus, M., Britto, P., Borkowsky, W., Burchett, S., Smith, B., Mofenson, L., Sullivan, J. L., the PACTG 356 Investigators, (1999). Dynamics of Human Immunodeficiency Virus Type 1 Replication in Vertically Infected Infants. J. Virol. 73: 362-367 [Abstract] [Full Text]  
• (1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics 102: 1005-1062 [Full Text]  
• Clarke, M., Chalmers, I. (1998). Discussion Sections in Reports of Controlled Trials Published in General Medical Journals: Islands in Search of Continents?. JAMA 280: 280-282 [Abstract] [Full Text]  
• Luzuriaga, K., Sullivan, J. L. (1998). Prevention and Treatment of Pediatric HIV Infection. JAMA 280: 17-18 [Full Text]  
• Palumbo, P. E., Raskino, C., Fiscus, S., Pahwa, S., Fowler, M. G., Spector, S. A., Englund, J. A., Baker, C. J. (1998). Predictive Value of Quantitative Plasma HIV RNA and CD4+ Lymphocyte Count in HIV-Infected Infants and Children. JAMA 279: 756-761 [Abstract] [Full Text]  
• Mueller, B. U., Nelson Jr, R. P., Sleasman, J., Zuckerman, J., Heath-Chiozzi, M., Steinberg, S. M., Balis, F. M., Brouwers, P., Hsu, A., Saulis, R., Sei, S., Wood, L. V., Zeichner, S., Katz, T. T. K., Higham, C., Aker, D., Edgerly, M., Jarosinski, P., Serchuck, L., Whitcup, S. M., Pizzuti, D., Pizzo, P. A. (1998). A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection. Pediatrics 101: 335-343 [Abstract] [Full Text]  
• Landry, K., Smith, T. (1998). Neurocognitive Effects of HIV Infection on Young Children: Implications for Assessment. Topics in Early Childhood Special Education 18: 160-169 [Abstract]  
• Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., Richman, D. D. (1997). Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia. Science 278: 1291-1295 [Abstract] [Full Text]  
• Frenkel, L. M., Melvin, A. J. (1997). Issues Regarding Antiretroviral Treatment for Patients With HIV-1 Infection. JAMA 278: 1234-1234 [Abstract]  
• (1997). Nonnucleoside Reverse Transcriptase Inhibitors. AIDS Clin Care 1997: 1-1 [Full Text]  
• Englund, J. A., Baker, C. J., Raskino, C., McKinney, R. E., Petrie, B., Fowler, M. G., Pearson, D., Gershon, A., McSherry, G. D., Abrams, E. J., Schliozberg, J., Sullivan, J. L., Behrman, R., Connor, J. C., Hetherington, S., Lifschitz, M. H., McLaren, C., Mendez, H., Millison, K., Moye, J., Nozyce, M., O'Donnell, K., Purdue, L., Schoenfeld, D., Scott, G., Spector, S. A., Wara, D. W., The AIDS Clinical Trials Group (ACTG) Study 152 Te, (1997). Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children. NEJM 336: 1704-1712 [Abstract] [Full Text]